As required by the Generic Drug User Fee Amendments of 2012, FDA has announced the 2016 rates for the following user fees:
These fees are collected to ensure FDA has the needed funds to employ the staff needed to review drugs in a timely manner, thus getting drugs approved and to market in a more efficient time frame. The rates are amended annually and are effective each fiscal year, from October 1 to September 30.
The generic drug user fee rates for fiscal year 2016 are as follows:
Applications:
Fee Category |
Fee Rates for FY 2016 |
Abbreviated New Drug Application (ANDA) | $76, 030 |
Prior Approval Supplement (PAS) to ANDA | $38,020 |
Drug Master File (DMF) | $42,170 |
Facilities:
Fee Category |
Fee Rates for FY 2016 |
Active Pharmaceutical Ingredient (API) - Domestic | $40,867 |
API – Foreign | $55,867 |
Finished Dosage Form (FDF) – Domestic | $243,905 |
FDF – Foreign | $258,905 |
August 4, 2016
FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...
August 7, 2018
On Friday, July 27th, FDA released a notice with updated generic drug user fee rates for fiscal year 2019. Under GDUFA II, user fees should total $493,600,000 each year, adjusted for inflation. The...
August 2, 2016
The Prescription Drug User Fee Amendments of 2012 (PDUFA V) allows FDA to collect user fees for the review of applications concerning human drug and biological products, the establishments where...